HOME >> BIOLOGY >> NEWS
CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell

SAN ANTONIO -- The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung. CTRC is one of only three sites in the United States, and the only in Texas, enrolling patients. The novel anti-cancer therapy, REOLYSIN, is a living virus, not a chemotherapy drug, that is toxic to cancer cells but not harmful to normal cells. This novel therapy, using a living virus, is the first of its kind available at CTRC. According to Monica Mita, MD, principal investigator at the CTRC Institute for Drug Development, REOLYSINs name was derived from the human reovirus, a mild virus that occurs naturally in the environment.

This novel therapy has shown success because the reovirus replicates in and destroys the cancer cells within the patients body, said Mita. Cancer cells have several molecular and genetic abnormalities. In normal, healthy cells, the reovirus is unable to reproduce because of an enzyme named PKR. The enzyme is suppressed in cancer cells, and therefore the reovirus can replicate in the cancer cell and kill it.

REOLYSIN typifies the true targeted therapy approach that seeks to use fundamental differences between cancer and normal cells as the basis for effective anti-cancer approaches and we are thus very excited about the this study, said Francis Giles, MD, director of the CTRC Institute for Drug Development.

Eligible patients are those who have a bone or soft tissue sarcoma that has spread to the lung and who are deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumors, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

The second patient to enroll in the st
'"/>

Contact: Jill. B. Byrd
jbyrd@ctrc.net
210-450-5550
Cancer Therapy & Research Center (CTRC)
24-Jul-2007


Page: 1 2

Related biology news :

1. Saudi Arabias KAUST names WHOI first research partner
2. Which came first, the moth or the cactus?
3. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
4. Seawater intrusion is the first cause of contamination of coastal aquifers
5. Camera-shy deer caught for first time
6. New joint replacement material developed at MGH put to first clinical use
7. Liverpool amongst first in UK to install unique DNA sequencing technology
8. A first-principles model of early evolution
9. Worlds first X-ray free electron laser is on course to completion
10. Scientists identify first gene linked to scoliosis
11. Which came first: Primates ability to see colorful food or see colorful sex?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/22/2018)... ... December 21, 2018 , ... ... and hosted the Boston Healthcare Drinks event featuring Helen Chen, Greater China Managing ... China.” , The discussion was moderated by patent attorney David J. Dykeman ...
(Date:12/19/2018)... (PRWEB) , ... December 19, 2018 , ... InTouchMD’s flagship ... innovative products in healthcare for 2018. , PM360 is featuring the recognition in ... products and services offered to the pharmaceutical and medical device industries. , “This ...
(Date:12/18/2018)... ... December 18, 2018 , ... ... cancers and other serious diseases, today announced the publication of an early feasibility ... treatment of rGBM. , The publication of the study, An Early Feasibility ...
Breaking Biology News(10 mins):
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today announced ... candidate, code-named "KM-819." KM-819 is an orally active small molecule that is ... Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was to ...
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection and desire to improve ... the European Union (EU) on the horizon, Jim Kasic, president and CEO of Boulder ... the EU Medical Device Regulation (MDR), digital health, and big data are just a ...
(Date:12/18/2018)... ... ... Patients with early stages of breast cancer who undergo partial breast proton ... irradiation, a new study suggests. , Patients with early stage breast cancer — stage ... the cancerous tumor because there is a 30 to 40 percent change the disease ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
Breaking Biology Technology:
Cached News: